In the US, cardiovascular disease is the leading cause of mortality and morbidity among patients with type 2 diabetes (T2D).1 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recommended treatment option for glycemic control in patients with diabetes, have recently emerged as a cardioprotective therapy.2 Multiple large randomized clinical trials3,4,5 have shown GLP-1 RAs prevent cardiovascular events among patients with T2D, particularly patients with established atherosclerotic cardiovascular disease (ASCVD). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.